Co-design of Guidance for Patient and Public Involvement in Psychedelic Research.
James B. Close,Julia Bornemann,Maria Piggin,Sandra Jayacodi,Lisa Xiaolu Luan,Robin L. Carhart-Harris,Meg J. Spriggs +6 more
Reads0
Chats0
TLDR
A steering group was formed to design and run a co-design workshop alongside public collaborators as discussed by the authors, which focused on the essential importance of trust, learning, purpose and inclusivity.Abstract:
Within the context of scientific research, patient and public involvement (PPI) is defined as research performed "with" or "by" patients and members of the public, rather than "to," "about", or "for" them. When carried out systematically and thoughtfully, PPI has the potential to strengthen the quality and impact of research by fostering accountability, transparency, and relevance. There exist numerous guidelines, frameworks and tools for supporting PPI, however, these do not account for the unique challenges faced in psychedelic research. This paper describes the co-design of guidance intended to help build, evaluate and improve PPI in psychedelic research. A steering group was formed to design and run a co-design workshop alongside public collaborators. Insights from this workshop were analyzed and refined into a comprehensive and readily usable guide for planning PPI specific to the field of psychedelic research. Core values emerging from the process focused on the essential importance of trust, learning, purpose and inclusivity. It is hoped that this guidance will be a starting point for incorporating PPI in future psychedelic research, so that it can grow and adapt as this burgeoning field of research progresses.read more
Citations
More filters
Journal ArticleDOI
Therapeutic Alliance and Rapport Modulate Responses to Psilocybin Assisted Therapy for Depression
Robert A. Murphy,Hannes Kettner,Richard J. Zeifman,Bruna Giribaldi,Laura Kartner,Jonny Martell,Tim R H Read,A Murphy-Beiner,Michelle Baker-Jones,David Nutt,David Erritzoe,Rosalind Watts,Robin L. Carhart-Harris +12 more
TL;DR: In this article , the authors investigated the relationship between therapeutic alliance and rapport, the quality of the acute psychedelic experience and treatment outcomes in a trial of psychedelic-assisted therapy for moderate-severe depressive disorder.
Journal ArticleDOI
Study Protocol for "Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study".
Meg J. Spriggs,Hannah M. Douglass,Rebecca J. Park,Tim Read,Jennifer L. Danby,Frederico J. C. de Magalhães,Kirsty L. Alderton,Tim M. Williams,Allan Blemings,Adele Lafrance,Dasha Nicholls,David Erritzoe,David J. Nutt,Robin L. Carhart-Harris +13 more
TL;DR: In this article, the authors present an overview of the ways through which Public Patient Involvement (PPI) has informed a trial of psilocybin-assisted therapy for anorexia nervosa (AN) currently underway at Imperial College London.
Journal ArticleDOI
Self-Medication for Chronic Pain Using Classic Psychedelics: A Qualitative Investigation to Inform Future Research
Julia Bornemann,James B. Close,Meg J. Spriggs,Robin L. Carhart-Harris,Robin L. Carhart-Harris,Leor Roseman +5 more
TL;DR: In this paper, a pre-trial PI study was conducted to understand how those with lived experience of chronic pain self-medicate with psychedelic drugs, and to establish, in detail, their therapeutic protocols and practices for success.
Journal ArticleDOI
ARC: a framework for access, reciprocity and conduct in psychedelic therapies
Meg J. Spriggs,A Murphy-Beiner,Robert A. Murphy,Julia Bornemann,Hannah Thurgur,Anne Katrin Schlag +5 more
TL;DR: The Access, Reciprocity and Conduct (ARC) framework as mentioned in this paper is a framework for a culturally informed ethical infrastructure for psychedelic therapies, which prioritizes equal access to PAT for those in need of mental health treatment, promotes the safety of those delivering and receiving PAT in clinical contexts, and respects the traditional and spiritual uses of psychedelic medicines which often precede their clinical use.
References
More filters
Journal ArticleDOI
Patient engagement in research: a systematic review
Juan Pablo Domecq,Gabriela Prutsky,Tarig Elraiyah,Zhen Wang,Mohammed Nabhan,Nathan D. Shippee,Juan P. Brito,Kasey R. Boehmer,Rim Hasan,Rim Hasan,Belal Firwana,Belal Firwana,Patricia J. Erwin,David T. Eton,Jeff A. Sloan,Victor M. Montori,Noor Asi,Abd Moain Abu Dabrh,Mohammad Hassan Murad +18 more
TL;DR: Patient engagement in healthcare research is likely feasible in many settings but can become tokenistic and research dedicated to identifying the best methods to achieve engagement is lacking and clearly needed.
Journal ArticleDOI
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.
TL;DR: When administered under supportive conditions, psilocybin occasioned experiences similar to spontaneously occurring mystical experiences, and the ability to occasion such experiences prospectively will allow rigorous scientific investigations of their causes and consequences.
Journal ArticleDOI
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial.
Roland R. Griffiths,Matthew W. Johnson,Michael A. Carducci,Annie Umbricht,William A. Richards,Brian D Richards,Mary P Cosimano,Margaret A. Klinedinst +7 more
TL;DR: High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety.
Journal ArticleDOI
Mapping the impact of patient and public involvement on health and social care research: a systematic review
Jo Brett,Sophie Staniszewska,Carole Mockford,Sandra Herron-Marx,John R. Hughes,Colin Tysall,Rashida Suleman +6 more
TL;DR: There is an increasing international interest in patient and public involvement in research, yet relatively little robust evidence exists about its impact on health and social care research.
Journal ArticleDOI
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study
Robin L. Carhart-Harris,Mark Bolstridge,James Rucker,Camilla M. Day,David Erritzoe,Mendel Kaelen,Michael A P Bloomfield,James Rickard,Ben Forbes,Amanda Feilding,David Taylor,Steve Pilling,Valerie Curran,David J. Nutt +13 more
TL;DR: Preliminary support for the safety and efficacy of psilocybin for treatment-resistant depression is provided and motivates further trials, with more rigorous designs, to better examine the therapeutic potential of this approach.
Related Papers (5)
Towards a pedagogy for patient and public involvement in medical education.
Sam Regan de Bere,Suzanne Nunn +1 more